Table 1. Characteristics of patients with and without invasive mold diseases (IMDs).
| Characteristic | IMD group n (%) | Control group n (%) |
| No. of patients | 79 | 68 |
| No. of clinical encounters1 | 79 (51) | 75 (49) |
| Male gender | 48 (61) | 35 (51) |
| Age, mean (range) years | 53 (20–89) | 51 (18–89) |
| Underlying disease | ||
| AML | 32 (41) | 35 (51) |
| ALL | 14 (18) | 14 (19) |
| Lymphoma | 15 (19) | 12 (16) |
| Chronic leukaemia | 7 (8.9) | 1 (1.3) |
| MDS/transformed MDS | 6 (7.6) | 2 (2.7) |
| Multiple myeloma | 3 (3.8) | 3 (4) |
| Other | 2 (2.5) | 5 (6.7) |
| Neutropenia (≤0.5 cells/L) present | 65 (82) | 56 (75) |
| Median duration of neutropenia (IQR), days | 18 (8–45) | 19 (5–39) |
| HSCT | 36 (46) | 39 (52) |
| Allogeneic | 31/36 (86) | 30/39 (77) |
| Autologous | 5/36 (14) | 9/39 (23) |
| Characteristics of IMDs, n = 79 | NA | |
| Probable/proven IMDs | 33 (42) | |
| Possible IMDs | 46 (58) | |
| Site of infection | ||
| Lung | 67 (85) | |
| Sino-pulmonary | 3 (3.8) | |
| Sinus | 2 (2.5) | |
| Hepatosplenic | 2 (2.5) | |
| Disseminated | 4 (5.1) | |
| Organism | ||
| Aspergillus fumigatus | 13 | |
| Non-fumigatus Aspergillus species (A. niger, A. flavus) | 4 | |
| Fungal hyphae resembling Aspergillus species | 3 | |
| Scedosporium species | 4 | |
| Any positive PCR | 2 | |
| Rhizopus species | 4 | |
| Other molds (Acrophialophora fusispora, Paecilomyces lilacinus) | 2 | |
| Candida glabrata (co-infection with S. Prolificans fungaemia) | 1 |
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; IQR, inter-quartile range; HSCT, haematopoietic stem cell transplant.
1
Clinical encounter defined from admission to either discharge, death or transfer and for up to 12-weeks after where applicable.